Stock listing
NASDAQ:SLGL Sol-Gel Technologies Ltd. Stock
Home listing (NASDAQ) of Sol-Gel Technologies Ltd.
Follow Sol-Gel Technologies Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:SLGL
$55.17 USD +1.81 (+3.4%)
Close on Nov 20, 2026
- Day range
- $51.81 – $56.16 USDNov 20, 2026
- Volume
- 24,365 sharesNov 20, 2026
- Market cap
- $180.6M USDAt the close on Nov 20, 2026 · price × 3.27M shares outstanding
- 52-week range
- $34.47 – $97.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.15M USDMedian day 41,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SLGL · Home | $55.17 USD | +1.81 (+3.4%) | 24,365 | $52.43 | $56.16 | $51.81 | $53.36 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLGL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $55.17 | +1.81 | +3.4% | $52.43 | $56.16 | $51.81 | 24,365 | |
| $53.36 | +0.53 | +1.0% | $54.15 | $56.16 | $53.36 | 29,438 | |
| $52.83 | -2.13 | -3.9% | $55.50 | $55.94 | $50.61 | 63,515 | |
| $54.96 | -0.16 | -0.3% | $55.91 | $58.43 | $53.98 | 83,704 | |
| $55.12 | -1.13 | -2.0% | $56.80 | $57.78 | $53.44 | 34,619 | |
| $56.25 | -7.15 | -11.3% | $62.03 | $63.00 | $54.00 | 44,837 | |
| $63.40 | +1.90 | +3.1% | $62.99 | $63.72 | $62.01 | 14,167 | |
| $61.50 | -0.24 | -0.4% | $61.37 | $62.80 | $61.00 | 9,811 | |
| $61.74 | +0.73 | +1.2% | $62.10 | $64.70 | $61.21 | 19,118 | |
| $61.01 | -2.00 | -3.2% | $62.75 | $65.25 | $60.01 | 27,672 | |
| $63.01 | -2.99 | -4.5% | $66.00 | $66.50 | $63.00 | 8,788 | |
| $66.00 | +2.19 | +3.4% | $63.82 | $67.30 | $63.50 | 32,796 | |
| $63.81 | -1.88 | -2.9% | $67.59 | $68.00 | $63.81 | 34,958 | |
| $65.69 | -2.66 | -3.9% | $67.29 | $67.29 | $63.98 | 55,993 | |
| $68.35 | -0.31 | -0.5% | $69.49 | $70.15 | $67.14 | 33,517 | |
| $68.66 | +0.48 | +0.7% | $69.10 | $71.35 | $68.01 | 24,759 | |
| $68.18 | -0.01 | 0.0% | $68.31 | $69.40 | $65.50 | 25,634 | |
| $68.19 | -1.44 | -2.1% | $72.00 | $72.00 | $68.19 | 38,785 | |
| $69.63 | +0.18 | +0.3% | $70.89 | $71.50 | $68.60 | 47,643 | |
| $69.45 | +2.06 | +3.1% | $67.37 | $70.63 | $67.13 | 57,800 | |
| $67.39 | +1.67 | +2.5% | $65.69 | $67.40 | $63.53 | 46,200 | |
| $65.72 | -0.09 | -0.1% | $66.44 | $69.36 | $64.50 | 59,500 | |
| $65.81 | +0.83 | +1.3% | $63.68 | $66.98 | $63.68 | 44,900 | |
| $64.98 | +0.73 | +1.1% | $67.39 | $67.39 | $64.06 | 13,900 | |
| $64.25 | -4.45 | -6.5% | $69.10 | $69.10 | $62.66 | 69,800 | |
| $68.70 | -0.80 | -1.2% | $70.00 | $70.00 | $67.51 | 41,200 | |
| $69.50 | +1.20 | +1.8% | $69.78 | $71.67 | $68.07 | 26,800 | |
| $68.30 | -4.10 | -5.7% | $72.81 | $72.81 | $68.30 | 33,700 | |
| $72.40 | +0.63 | +0.9% | $71.77 | $73.11 | $69.50 | 29,000 | |
| $71.77 | +1.43 | +2.0% | $69.85 | $72.37 | $68.78 | 31,500 | |
| $70.34 | -1.605 | -2.2% | $70.46 | $70.92 | $66.52 | 41,000 | |
| $71.95 | -3.695 | -4.9% | $74.97 | $75.07 | $71.28 | 31,300 | |
| $75.64 | -3.31 | -4.2% | $78.95 | $79.50 | $73.95 | 44,000 | |
| $78.95 | +6.95 | +9.7% | $71.20 | $79.01 | $71.20 | 29,200 | |
| $72.00 | -1.00 | -1.4% | $72.88 | $74.35 | $70.84 | 44,400 | |
| $73.00 | -1.28 | -1.7% | $74.42 | $74.42 | $70.75 | 32,800 | |
| $74.28 | +2.03 | +2.8% | $73.33 | $77.67 | $72.87 | 39,200 | |
| $72.25 | +2.80 | +4.0% | $69.96 | $72.79 | $69.20 | 30,700 | |
| $69.45 | +2.60 | +3.9% | $66.72 | $72.00 | $66.72 | 58,000 | |
| $66.85 | +6.11 | +10.1% | $61.25 | $67.29 | $61.05 | 26,100 | |
| $60.74 | +1.03 | +1.7% | $59.57 | $62.63 | $58.42 | 66,900 | |
| $59.71 | -1.24 | -2.0% | $61.00 | $61.77 | $58.73 | 70,700 | |
| $60.95 | +1.67 | +2.8% | $58.79 | $63.70 | $58.79 | 79,700 | |
| $59.28 | -0.72 | -1.2% | $59.83 | $60.00 | $58.30 | 29,800 | |
| $60.00 | -4.54 | -7.0% | $64.17 | $64.61 | $60.00 | 45,800 | |
| $64.54 | +1.10 | +1.7% | $62.65 | $65.44 | $62.64 | 45,100 | |
| $63.44 | -0.96 | -1.5% | $64.46 | $64.46 | $60.98 | 54,500 | |
| $64.40 | -0.78 | -1.2% | $64.25 | $66.50 | $64.00 | 59,100 | |
| $65.18 | -0.76 | -1.2% | $65.69 | $66.39 | $64.02 | 27,900 | |
| $65.94 | -0.85 | -1.3% | $67.42 | $67.62 | $65.61 | 25,000 | |
| $66.79 | -2.39 | -3.5% | $69.40 | $69.57 | $66.10 | 84,200 | |
| $69.18 | -0.19 | -0.3% | $70.99 | $70.99 | $68.42 | 47,500 | |
| $69.37 | -0.15 | -0.2% | $69.06 | $70.20 | $67.79 | 38,600 | |
| $69.52 | -0.58 | -0.8% | $70.17 | $70.80 | $68.39 | 29,600 | |
| $70.10 | -0.33 | -0.5% | $71.33 | $72.99 | $69.84 | 58,100 | |
| $70.43 | +0.91 | +1.3% | $69.48 | $72.09 | $68.00 | 97,700 | |
| $69.52 | +0.42 | +0.6% | $70.26 | $72.76 | $69.02 | 130,200 | |
| $69.10 | +0.29 | +0.4% | $67.77 | $70.93 | $66.75 | 111,300 | |
| $68.81 | -3.76 | -5.2% | $72.61 | $76.00 | $66.15 | 147,800 | |
| $72.57 | -6.86 | -8.6% | $80.45 | $80.70 | $71.97 | 58,700 | |
| $79.43 | -2.29 | -2.8% | $81.20 | $81.80 | $77.22 | 68,600 | |
| $81.72 | +4.33 | +5.6% | $78.88 | $82.19 | $78.88 | 56,000 | |
| $77.39 | -0.34 | -0.4% | $76.99 | $78.41 | $75.38 | 59,800 | |
| $77.73 | -0.765 | -1.0% | $81.92 | $81.92 | $77.17 | 33,300 | |
| $78.50 | -0.095 | -0.1% | $78.47 | $81.00 | $76.87 | 28,600 |
Splits
1 split · NASDAQ:SLGL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:SLGL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Latest deck · Oct 14, 2026
Investor Day (October 2026)
Investor day · 93 slides
Latest news
Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 12, 2026
Closed $56.25 (-11.3%) on Nov 12, 2026
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Sep 30, 2026
Closed $74.28 (+2.8%) on Sep 30, 2026
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Sep 17, 2026
Closed $64.54 (+1.7%) on Sep 17, 2026
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 20, 2026
Closed $78.50 (-0.1%) on Aug 20, 2026
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 28, 2026
Closed $75.28 (+2.0%) on May 28, 2026
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Mar 23, 2026
Closed $66.20 (-9.3%) on Mar 23, 2026
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Mar 19, 2026
Closed $81.71 (+8.5%) on Mar 19, 2026
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
Dec 17, 2025
Closed $41.15 (-2.3%) on Dec 17, 2025
Sol-Gel Technologies Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 95 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 29 decks · latest Oct 14, 2026
Where Sol-Gel Technologies Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SLGL · Home listing · This page | NASDAQ | United States | USD |
| Frankfurt:4SG | Frankfurt | Germany | EUR |
| LS Exchange:A2JDHD | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JDHD | Lang & Schwarz | Germany | EUR |
| BOATS:SLGL | BOATS | United States | USD |
| Stuttgart:4SG | Stuttgart | Germany | EUR |
| Tradegate:4SG | Tradegate | Germany | EUR |
Valuation
EV/sales 95.4× against a median of 33.5×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $137.0M USD
- P/E
- Loss
- EV/sales
- 95.4×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 4.2×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.67
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Inhibikase Therapeutics, Inc. · NASDAQ:IKT | US$185.2M | −US$8.17M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.50 |
| Inventage Lab, Inc. · KRX:389470 | US$184.8M | US$112.6M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.0M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Nanexa AB · OMXSTO:NANEXA | US$175.3M | US$170.3M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Median of the others | US$180.8M | US$100.6M | 33.5× | 1.7× | −222.8% | 0.0× | 1.35 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 152.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -7.75 · 3 analysts
- Revenue, year to Dec 2026
- 1.02M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Alon Seri-Levy | Chief Executive Officer and Director |
| Mori Arkin | Chief Executive Officer, Chairman |
| Eyal Ben-Or | Chief Financial Officer |
| Moshe Arkin | Executive Chairman of the Board of Directors |
Board
| Director | Role |
|---|---|
| Mori Arkin | Chief Executive Officer, Chairman |
| Moshe Arkin | Executive Chairman of the Board of Directors |
| Alon Seri-Levy | Chief Executive Officer and Director |
| Hani Lerman | Director |
| Itai Arkin | Director |
| Jonathan B. Siegal | Independent Director |
| Ran Gottfried | Director |
| Sharon Kochan | Director |
| Shmuel Ben Zvi | Independent Director |
| Yaffa Krindel-Sieradzki | Independent Director |
| Yuval Yanai | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −11.3% |
| Q2 2026 | Aug 20, 2026 · Before open | −0.1% |
| Q1 2026 | May 28, 2026 · Before open | +2.0% |
| Q4 2025 | Mar 11, 2026 | −3.8% |
| Q3 2025 | Nov 20, 2025 · Before open | −0.8% |
| Q2 2025 | Aug 15, 2025 · Before open | +1.3% |
| Q1 2025 | May 19, 2025 · Before open | +3.3% |
| Q4 2024 | Mar 31, 2025 | −10.7% |
| Q3 2024 | Nov 15, 2024 · Before open | +3.0% |
| Q2 2024 | Aug 16, 2024 · Before open | +2.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 20, 2024 · Before open | −6.0% |
| Q4 2023 | Mar 13, 2024 · Before open | 0.0% |
| Q3 2023 | Nov 9, 2023 · Before open | +3.5% |
| Q2 2023 | Aug 10, 2023 · Before open | +1.6% |
| Q1 2023 | May 12, 2023 · Before open | +2.4% |
| Q4 2022 | Mar 10, 2023 · Before open | −4.0% |
| Q3 2022 | Nov 10, 2022 · Before open | +0.2% |
| Q2 2022 | Aug 4, 2022 · Before open | −6.6% |
| Q1 2022 | May 13, 2022 · Before open | +6.0% |
| Q4 2021 | Mar 30, 2022 · Before open | +2.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (October 2026) | Investor day | 93 slides | Oct 14, 2026 |
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 22 slides | September 2026 |
| Investor Presentation (February 2023) | Investor deck | 19 slides | Feb 2, 2023 |
| Investor Presentation (June 2022) | Investor deck | 22 slides | Jun 8, 2022 |
| Investor Presentation (May 2022) | Investor deck | 22 slides | May 16, 2022 |
| Investor Presentation (January 2022) | Investor deck | 17 slides | Jan 5, 2022 |
| Investor Presentation (November 2021) | Investor deck | 19 slides | Nov 16, 2021 |
| Investor Presentation (September 2021) | Investor deck | 25 slides | Sep 9, 2021 |
| Investor Presentation (August 2021) | Investor deck | 25 slides | Aug 4, 2021 |
All 29 decks
IPO
Priced at US$12.00 a share on Jan 31, 2018.
- Price
- US$12.00 a share
- Shares offered
- 6,250,000 ordinary shares
- Offering size
- US$75 million
- Underwriters' option
- Up to 937,500 more shares
- Listing
- SLGL on the Nasdaq Global Market
- Underwriters
- Jefferies, BMO Capital Markets, JMP Securities, Raymond James · In the order on the cover
- Shares delivered
- On or about Feb 5, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 28, 2016 |
| Filed publicly | Aug 29, 2017 |
| Amended 5 times | Newest Jan 30, 2018 |
| Shares registered with an exchange | Jan 26, 2018 |
| Declared effective by the SEC | Jan 31, 2018 |
| Final prospectus, with the price | Feb 2, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 2, 2018 |
| EFFECT · Notice that a registration is effective | Jan 31, 2018 |
| CERT · Exchange's certificate of listing | Jan 31, 2018 |
| FWP · Free writing prospectus | Jan 30, 2018 |
| F-1/A · Registration statement, amended | Jan 30, 2018 |
| UPLOAD · Letter from the SEC | Jan 29, 2018 |
| CORRESP · Letter to the SEC | Jan 29, 2018 |
| CORRESP · Letter to the SEC | Jan 29, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 26, 2018 |
| F-1/A · Registration statement, amended | Jan 23, 2018 |
All 29 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 17, 2018 |
| UPLOAD · Letter from the SEC | Jan 16, 2018 |
| CORRESP · Letter to the SEC | Dec 29, 2017 |
| F-1/A · Registration statement, amended | Dec 29, 2017 |
| F-1/A · Registration statement, amended | Sep 20, 2017 |
| UPLOAD · Letter from the SEC | Sep 11, 2017 |
| F-1/A · Registration statement, amended | Sep 6, 2017 |
| CORRESP · Letter to the SEC | Sep 1, 2017 |
| CORRESP · Letter to the SEC | Aug 29, 2017 |
| F-1 · Registration statement | Aug 29, 2017 |
| UPLOAD · Letter from the SEC | Aug 28, 2017 |
| DRS/A · Draft registration statement, amended | Aug 11, 2017 |
| DRSLTR · Letter to the SEC with a draft | Jun 6, 2017 |
| DRS/A · Draft registration statement, amended | Jun 6, 2017 |
| UPLOAD · Letter from the SEC | May 1, 2017 |
| DRSLTR · Letter to the SEC with a draft | Apr 3, 2017 |
| DRS/A · Draft registration statement, amended | Apr 3, 2017 |
| UPLOAD · Letter from the SEC | Oct 27, 2016 |
| DRS · Draft registration statement | Sep 28, 2016 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 2, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.4M | 11.5M | 1.55M | 3.88M | 31.3M | 8.77M | 22.9M | 129.0K | 174.0K | 0 |
| Cost of revenue | 109.0K | 233.0K | 342.0K | 12.7M | 20.4M | 27.9M | 40.6M | 28.1M | 300.0K | 359.0K |
| Gross profit | 19.4M | 11.5M | 1.55M | -8.80M | 10.9M | 8.77M | -17.7M | -28.0M | -126.0K | -359.0K |
| Research and development | 22.8M | 17.8M | 23.5M | 12.7M | 20.4M | 27.9M | 40.6M | 28.1M | 25.8M | 17.0M |
| Selling, general and administrative | 4.18M | 5.75M | 7.37M | 7.45M | 8.45M | 11.1M | 8.28M | 5.50M | 6.00M | 3.73M |
| Operating income | -7.54M | -12.0M | -29.3M | -16.2M | 2.96M | -30.2M | -25.9M | -33.5M | -31.6M | -20.8M |
| Depreciation and amortization | 109.0K | 233.0K | 342.0K | 562.0K | 880.0K | 946.0K | 887.0K | 762.0K | 471.0K | 359.0K |
| EBITDA | -7.43M | -11.8M | -29.0M | -15.7M | 3.84M | -29.3M | -25.1M | -32.8M | -31.2M | -20.4M |
| Interest expense | 1.32M | 880.0K | 0 | 1.37M | 0 | 0 | 0 | |||
| Income before tax | -6.13M | -10.6M | -27.2M | -14.9M | 3.22M | -29.3M | -24.6M | -32.2M | -31.6M | -20.8M |
| Income tax | 0 | 0 | 0 | -1.32M | 0 | 0 | 33.0K | -1.32M | -65.0K | 15.0K |
| Net income | -6.13M | -10.6M | -27.2M | -14.9M | 3.22M | -29.3M | -24.6M | -32.2M | -31.6M | -20.8M |
| Earnings per share, basic | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 | -1.30 | -1.26 | 1.80 | 5.02 | 3.30 |
| Earnings per share, diluted | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 | -1.30 | -1.26 | 1.80 | 5.02 | 3.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.0M | 19.5M | 7.51M | 12.4M | 20.1M | 7.12M | 9.41M | 5.33M | 5.02M | 7.00M |
| Short-term investments | 13.0M | 4.42M | 20.5M | 8.68M | 1.71M | 21.7M | 41.0M | 56.7M | 4.00M | |
| Receivables | 1.97M | 3.60M | 377.0K | 62.0K | 13.1M | 2.15M | 4.12M | |||
| Inventory | 1 | 1 | 1 | |||||||
| Current assets | 27.0M | 31.3M | 41.2M | 43.1M | 57.1M | 53.4M | 55.8M | 66.0M | 10.5M | 8.30M |
| Property, plant and equipment | 140.0K | 202.0K | 434.0K | 660.0K | 1.05M | 1.82M | 2.31M | 2.60M | 2.31M | 798.0K |
| Total assets | 29.9M | 35.8M | 45.3M | 46.6M | 69.2M | 59.2M | 61.3M | 69.7M | 15.3M | 11.0M |
| Accounts payable | 735.0K | 1.26M | 154.0K | 251.0K | 766.0K | 1.20M | 1.71M | 2.92M | 534.0K | 667.0K |
| Current liabilities | 6.17M | 5.29M | 4.52M | 3.33M | 11.7M | 5.96M | 6.50M | 4.89M | 67.2M | 41.6M |
| Total debt | 991.0K | 1.31M | 1.65M | 772.0K | 1.59M | 1.97M | 2.04M | 65.3M | 37.3M | |
| Total liabilities | 7.11M | 7.00M | 6.64M | 4.42M | 13.6M | 8.31M | 8.84M | 5.77M | 68.0M | 42.3M |
| Shareholders' equity | 22.8M | 28.9M | 38.6M | 42.2M | 55.6M | 50.8M | 52.5M | 63.9M | -52.7M | -31.3M |
| Shares outstanding | 2.79M | 2.79M | 27.9M | 23.1M | 23.1M | 23.0M | 20.4M | 18.9M | 6.29M | 6.29M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 322.0K | -13.9M | -17.7M | -9.48M | -7.69M | -25.2M | -22.5M | -23.5M | -24.1M | -18.5M |
| Capital spending | -47.0K | -2.00K | -134.0K | -171.0K | -143.0K | -449.0K | -597.0K | -1.05M | -1.93M | -385.0K |
| Free cash flow | 275.0K | -13.9M | -17.9M | -9.65M | -7.83M | -25.7M | -23.1M | -24.5M | -26.0M | -18.9M |
| Cash from investing | -8.58M | 26.7M | -9.74M | 1.70M | 19.9M | -2.69M | 16.0M | -54.7M | -5.94M | -391.0K |
| Cash from financing | 6.00K | 0 | 21.8M | 15.0K | 837.0K | 26.5M | 10.6M | 78.8M | 28.0M | 20.0M |
| Share buybacks | 10.6M | 78.8M | ||||||||
| Change in cash | -8.44M | 12.8M | -5.74M | -7.64M | 13.0M | -1.49M | 4.09M | 651.0K | -1.98M | 1.11M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 17, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 17, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 333 filings. Open Filings
Cap table
Built by 6ix from Sol-Gel Technologies Ltd.’s releases · as of Sep 30, 2026
- Common shares
- 3,273,999
- Fully diluted
- 3,273,999
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 3,273,999 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 3,276,353 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Moshe Arkin Other companies: Odysight.ai Inc. (Director · Since at least Feb 10, 2025); Ophthalmic Imaging Systems (Director · Jun 24, 2009 – May 26, 2010 · Past); Perrigo Company plc (Director · Aug 16, 2006 – Aug 31, 2011 · Past) | Chairman of Board and CEO, Director · Since at least Mar 18, 2026 |
| Alon Seri-Levy | Chief Executive Officer and Director · Since at least Nov 15, 2024 |
| Eyal Ben-Or | Chief Financial Officer · Since at least Mar 18, 2026 |
| Hanna Lerman | Director · Since at least Mar 18, 2026 |
| Itai Arkin | Director · Since at least Mar 18, 2026 |
| Itzik Yosef | Chief Operating Officer · Since at least Mar 18, 2026 |
| Michael Glezin | Chief Business Officer · Since at least Mar 18, 2026 |
| Mori Arkin | Chief Executive Officer, Chairman · Since at least Sep 17, 2026 |
| Ofer Toledano | VP Research & Dev. · Since at least Mar 18, 2026 |
| Ofra Levy-Hacham | VP Clinical, Reg & Quality · Since at least Mar 18, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Ran Gottfried | Director · Since at least Mar 18, 2026 |
| Sharon Kochan | Director · Since at least Mar 18, 2026 |
| Stephen Van Deventer | Chairman and Chief Executive Officer · Feb 4, 2025 – Nov 5, 2026 · Past |
| Yuval Yanai | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about Sol-Gel Technologies Ltd.